Spots Global Cancer Trial Database for pediatric solid tumor
Every month we try and update this database with for pediatric solid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Molecular Characterization of Genetic Alterations in Pediatric Solid Tumors | NCT04773808 | Pediatric Solid... | - 18 Years | National Council of Scientific and Technical Research, Argentina | ||
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| HGS-ETR2 to Treat Children With Solid Tumors | NCT00428272 | Ewing's Sarcoma Osteosarcoma Neuroblastoma Rhabdomyosarcom... | Lexatumumab alo... Lexatumumab in ... Interferon gamm... Gamma 1b potent... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor | NCT05024331 | Pediatric Solid... | 19 Years - | Samsung Medical Center | ||
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | NCT04222413 | Advanced Solid ... Metastatic Panc... Pediatric Solid... Advanced Breast... Malignant Perip... Colorectal Neop... | Metarrestin | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients | NCT03222258 | Stage IV Breast... Stage IV Pancre... Stage IV Colon ... Stage IV Gastri... Stage IV Lung C... Stage IV Liver ... Malignant Hemat... Biliary Cancer ... Pediatric Leuke... Pediatric Lymph... Pediatric Brain... Pediatric Solid... | Early palliativ... Routine hospice... | - | Seoul National University Hospital | |
| A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) | NCT03455140 | Cancer Pediatric Solid... Pediatric AML Pediatric ALL | PEG- BCT-100 | 1 Year - 25 Years | University of Birmingham | |
| Pegteograstim in Children With Solid Tumors | NCT02787876 | Chemotherapy In... Pediatric Solid... | Pegteograstim | - 18 Years | Samsung Medical Center | |
| Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation | NCT02339753 | Pediatric Solid... | Carboplatin | - 19 Years | The Korean Society of Pediatric Hematology Oncology | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT04483778 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma Melanoma | second generati... second generati... Pembrolizumab | 0 Years - 26 Years | Seattle Children's Hospital | |
| GVAX Plus Checkpoint Blockade in Neuroblastoma | NCT04239040 | Neuroblastoma Pediatric Solid... | Tissue collecti... GVAX vaccine Nivolumab Ipilimumab | 1 Year - | Dana-Farber Cancer Institute | |
| Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging. | NCT04944875 | Pediatric Solid... Pediatric Brain... Pediatric Cance... | Group headphone Group music Group maternal ... | 3 Years - 12 Years | TC Erciyes University | |
| Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients | NCT03222258 | Stage IV Breast... Stage IV Pancre... Stage IV Colon ... Stage IV Gastri... Stage IV Lung C... Stage IV Liver ... Malignant Hemat... Biliary Cancer ... Pediatric Leuke... Pediatric Lymph... Pediatric Brain... Pediatric Solid... | Early palliativ... Routine hospice... | - | Seoul National University Hospital | |
| GVAX Plus Checkpoint Blockade in Neuroblastoma | NCT04239040 | Neuroblastoma Pediatric Solid... | Tissue collecti... GVAX vaccine Nivolumab Ipilimumab | 1 Year - | Dana-Farber Cancer Institute | |
| Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors | NCT05620862 | Pediatric Solid... | Mitoxantrone Hy... Irinotecan Vincristine | 2 Years - 21 Years | Sun Yat-sen University | |
| iCAT for Recurrent/Refractory/HR Solid Tumors | NCT01853345 | Pediatric Solid... Sarcoma Neuroblastoma Wilms Tumor | - 30 Years | Dana-Farber Cancer Institute | ||
| Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy | NCT05322187 | Transitional Ce... Hepatoblastoma Liver Cancer Pediatric Solid... Pediatric Cance... | PD-1 inhibitor | 5 Years - 14 Years | RenJi Hospital | |
| A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors | NCT02564198 | Pediatric Solid... Refractory Tumo... Recurrent Tumor CNS Malignancie... | Ramucirumab | 12 Months - 21 Years | Eli Lilly and Company | |
| Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | NCT05468359 | Refractory Soli... Hepatocellular ... Malignant Solid... Pediatric Cance... Pediatric Solid... Fibrolamellar C... | Atezolizumab Sorafenib Bevacizumab Cyclophosphamid... | - 30 Years | St. Jude Children's Research Hospital | |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | NCT04897321 | Pediatric Solid... Osteosarcoma Rhabdomyosarcom... Neuroblastoma Ewing Sarcoma Wilms Tumor Adrenocortical ... Desmoplastic Sm... Germ Cell Cance... Rhabdoid Tumor Clear Cell Sarc... Hepatoblastoma Melanoma Carcinoma Malignant Perip... Soft Tissue Sar... | Fludarabine Cyclophosphamid... MESNA B7-H3 CAR T cel... | - 21 Years | St. Jude Children's Research Hospital | |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT03618381 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma | second generati... second generati... | 1 Year - 30 Years | Seattle Children's Hospital | |
| The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study | NCT02520713 | Pediatric Solid... | Genetic testing... | - 30 Years | Dana-Farber Cancer Institute | |
| The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study | NCT02520713 | Pediatric Solid... | Genetic testing... | - 30 Years | Dana-Farber Cancer Institute | |
| Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy | NCT05322187 | Transitional Ce... Hepatoblastoma Liver Cancer Pediatric Solid... Pediatric Cance... | PD-1 inhibitor | 5 Years - 14 Years | RenJi Hospital | |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors | NCT03739827 | Malignant Solid... Other Neoplasms... Pediatric Solid... Refractory Soli... Solid Tumor | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | NCT04222413 | Advanced Solid ... Metastatic Panc... Pediatric Solid... Advanced Breast... Malignant Perip... Colorectal Neop... | Metarrestin | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) | NCT03455140 | Cancer Pediatric Solid... Pediatric AML Pediatric ALL | PEG- BCT-100 | 1 Year - 25 Years | University of Birmingham | |
| Molecular Characterization of Genetic Alterations in Pediatric Solid Tumors | NCT04773808 | Pediatric Solid... | - 18 Years | National Council of Scientific and Technical Research, Argentina |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
